Claims
- 1. An isolated nucleic acid encoding a polypeptide possessing β-(1,3) exoglucanase activity, said encoded polypeptide comprising:
a) an amino acid sequence depicted in SEQ ID NO: 2 from amino acid 1 to amino acid 785; b) an amino acid sequence depicted in SEQ ID NO: 2 from amino acid 22 to amino acid 785; or c) an amino acid sequence functionally equivalent to the amino acid sequence depicted in SEQ ID NO: 2.
- 2. An isolated nucleic acid according to claim 1, wherein said encoded polypeptide comprises an amino acid sequence having at least 70% homology to the amino acid sequence depicted in SEQ ID NO: 2.
- 3. An isolated nucleic acid according to claim 1, wherein said encoded polypeptide comprises an amino acid sequence having at least 75% homology to the amino acid sequence depicted in SEQ ID NO: 2.
- 4. An isolated nucleic acid according to claim 1, wherein said encoded polypeptide comprises an amino acid sequence having at least 80% homology to the amino acid sequence depicted in SEQ ID NO: 2.
- 5. An isolated nucleic acid according to claim 1, wherein said encoded polypeptide comprises an amino acid sequence having at least 85% homology to the amino acid sequence depicted in SEQ ID NO: 2.
- 6. An isolated nucleic acid according to claim 1, wherein said encoded polypeptide comprises an amino acid sequence having at least 90% homology to the amino acid sequence depicted in SEQ ID NO: 2.
- 7. An isolated nucleic acid according to claim 1, wherein said encoded polypeptide comprises an amino acid sequence having at least 95% homology to the amino acid sequence depicted in SEQ ID NO: 2.
- 8. An isolated polypeptide possessing β-(1,3) exoglucanase activity, said polypeptide comprising:
a) an amino acid sequence depicted in SEQ ID NO: 2 from amino acid 1 to amino acid 785; b) an amino acid sequence depicted in SEQ ID NO: 2 from amino acid 22 to amino acid 785; or c) a functionally equivalent amino acid sequence to the amino acid sequence depicted in SEQ ID NO: 2.
- 9. An isolated polypeptide according to claim 8, said polypeptide having a length of at least 50 amino acid residues of the amino acid sequence depicted in SEQ ID NO: 2.
- 10. An isolated polypeptide according to claim 8, said polypeptide having a length of at least 100 amino acid residues of the amino acid sequence depicted in SEQ ID NO: 2.
- 11. An isolated polypeptide according to claim 8, said polypeptide having a length of at least 200 amino acid residues of the amino acid sequence depicted in SEQ ID NO: 2.
- 12. An isolated polypeptide according to claim 8, said polypeptide having a length of at least 500 amino acid residues of the amino acid sequence depicted in SEQ ID NO: 2.
- 13. An isolated polypeptide according to claim 8, said polypeptide having a length of at least 600 amino acid residues of the amino acid sequence depicted in SEQ ID NO: 2.
- 14. An isolated polypeptide according to claim 8, said polypeptide having a length of at least 700 amino acid residues of the amino acid sequence depicted in SEQ ID NO: 2.
- 15. An isolated polypeptide according to claim 8, said polypeptide having a length of at least 750 amino acid residues of the amino acid sequence depicted in SEQ ID NO: 2.
- 16. An isolated polypeptide according to claim 8, said polypeptide comprising an amino acid sequence having at least 70% homology to the amino acid sequence depicted in SEQ ID NO: 2.
- 17. An isolated polypeptide according to claim 8, said polypeptide comprising an amino acid sequence having at least 75% homology to the amino acid sequence depicted in SEQ ID NO: 2.
- 18. An isolated polypeptide according to claim 8, said polypeptide comprising an amino acid sequence having at least 80% homology to the amino acid sequence depicted in SEQ ID NO: 2.
- 19. An isolated polypeptide according to claim 8, said polypeptide comprising an amino acid sequence having at least 85% homology to the amino acid sequence depicted in SEQ ID NO: 2.
- 20. An isolated polypeptide according to claim 8, said polypeptide comprising an amino acid sequence having at least 90% homology to the amino acid sequence depicted in SEQ ID NO: 2.
- 21. An isolated polypeptide according to claim 8, said polypeptide comprising an amino acid sequence having at least 95% homology to the amino acid sequence depicted in SEQ ID NO: 2.
- 22. An isolated nucleic acid according to claim 1, said nucleic acid comprising the nucleotide sequence depicted in SEQ ID NO: 1 from nucleotide 25 to nucleotide 2379.
- 23. An isolated nucleic acid according to claim 22, said nucleic acid comprising a nucleotide sequence having at least 70% homology to the nucleotide sequence depicted in SEQ ID NO: 1.
- 24. An isolated nucleic acid according to claim 22, said nucleic acid comprising a nucleotide sequence having at least 75% homology to the nucleotide sequence depicted in SEQ ID NO: 1.
- 25. An isolated nucleic acid according to claim 22, said nucleic acid comprising a nucleotide sequence having at least 80% homology to the nucleotide sequence depicted in SEQ ID NO: 1.
- 26. An isolated nucleic acid according to claim 22, said nucleic acid comprising a nucleotide sequence having at least 85% homology to the nucleotide sequence depicted in SEQ ID NO: 1.
- 27. An isolated nucleic acid according to claim 22, said nucleic acid comprising a nucleotide sequence having at least 90% homology to the nucleotide sequence depicted in SEQ ID NO: 1.
- 28. An isolated nucleic acid according to claim 22, said nucleic acid comprising a nucleotide sequence having at least 95% homology to the nucleotide sequence depicted in SEQ ID NO: 1.
- 29. A variant of the isolated nucleic acid according to claim 22, said variant comprising a functionally equivalent nucleotide sequence as the nucleotide sequence depicted in SEQ ID NO: 1.
- 30. A fragment of the isolated nucleic acid according to claim 22, said fragment comprising a functionally equivalent nucleotide sequence as the nucleotide sequence depicted in SEQ ID NO: 1.
- 31. A vector comprising a nucleic acid according to claim 1.
- 32. A cell other than Coniothyrium minitans, comprising a nucleic acid according to claim 1.
- 33. A cell according to claim 32, wherein the cell is Pichia pastoris.
- 34. A method for producing a polypeptide having glucanolytic activity, comprising the steps of:
a) culturing a cell comprising a nucleic acid according to claim 1 under conditions conducive to an expression of a polypeptide encoded by the nucleic acid; and, b) recovering the encoded polypeptide from the culture.
- 35. The method according to claim 34, wherein the cell is other than Coniothyrium minitans.
- 36. The method according to claim 35, wherein the cell is Pichia pastoris.
- 37. A method for producing a plant which expresses a nucleic acid according to claim 1, by introducing the nucleic acid into a plant cell so that the nucleic acid becomes incorporated into the genome of the plant cell.
- 38. The method according to claim 37, wherein the nucleic acid is introduced into the plant cell by particle bombardment or Agrobacterium-mediated transformation.
- 39. The method according to claim 38, wherein the expression of the nucleic acid in transformed plants is confirmed by polymerase chain reaction or Southern blot analyses.
- 40. A method for producing a plant which expresses a nucleic acid according to claim 1, comprising the steps of:
a) introducing the nucleic acid into a virus so that the nucleic acid becomes incorporated into the virus; and, b) infecting the plant with the virus so that the nucleic acid is expressed in the infected plant.
- 41. The method according to claim 37, wherein the plant is selected from: Brassica, Linum, Zea mays, Glycine, Soja, Gossypium, Arabidopsis thaliana, Triticum, Secale, Hordeum, Avena, Oryza, Sorghum, Solanum, Lycopersicon, Nicotiana and Cucurbita.
- 42. The method according to claim 40, wherein the plant is selected from: Brassica, Linum, Zea mays, Glycine, Soja, Gossypium, Arabidopsis thaliana, Triticum, Secale, Hordeum, Avena, Oryza, Sorghum, Solanum, Lycopersicon, Nicotiana and Cucurbita.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Patent Application Serial No. 60/170,168, filed on Dec. 10, 1999. To the extent that it is consistent herewith, the aforementioned application is incorporated herein by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60170168 |
Dec 1999 |
US |